<- Go Home
COMPASS Pathways plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Market Cap
$570.9M
Volume
1.6M
Cash and Equivalents
$185.9M
EBITDA
-$154.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$7.08
52 Week Low
$2.25
Dividend
N/A
Price / Book Value
15.20
Price / Earnings
-2.17
Price / Tangible Book Value
15.20
Enterprise Value
$420.1M
Enterprise Value / EBITDA
-2.77
Operating Income
-$154.6M
Return on Equity
205.81%
Return on Assets
-38.43
Cash and Short Term Investments
$185.9M
Debt
$35.2M
Equity
$37.6M
Revenue
N/A
Unlevered FCF
$54.5M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium